Clinical Asthma Phenotypes and Therapeutic Responses. (31st March 2013)

• Record Type: Journal Article
• Authors: Zedan, M.; Attia, G.; Zedan, M. M.; Osman, A.; Abo-Elkheir, N.; Maysara, N.; Barakat, T.; Gamil, N.
• Other Names: Brogan T. V. Academic Editor.; Fanconi S. Academic Editor.
• Is Part Of: ISRN pediatrics. Volume 2013(2013)
• Publication Date: 2013-03-31
• Subjects: Pediatrics -- Periodicals; Pediatrics; Pediatrics; Periodicals; 618.92
• DOI: 10.1155/2013/824781
• Languages: English
• ISSNs: 2090-469X

Abstract

Abstract : Asthma is a heterogeneous disease that means not all asthmatics respond to the same treatment. We hypothesize an approach to characterize asthma phenotypes based on symptomatology (shortness of breath (SOB), cough, and wheezy phenotypes) in correlation with airway inflammatory biomarkers and FEV1. We aimed to detect whether those clinical phenotypes have an impact on the response to asthma medications. Two hundred three asthmatic children were allocated randomly to receive either montelukast (5 mg at bed time) or fluticasone propionate (100 ug twice daily) for 8 consecutive weeks. Serum concentrations of IL-2Rs, ICAM-1, VCAM-1, total IgE, eosinophilic %, eosinophil cationic protein (ECP), and FEV1 were done before and after treatment to patients and once to controls. Children who have SOB were found to have higher levels of total sIgE, older age, and longer disease duration, and they responded to fluticasone alone. Cough group was found to have higher levels of eosinophilic % and sECP, younger age, shorter disease duration and responded to montelukast alone. Wheezy group showed mixed pattern and responded to both medications. Conclusion. Although there is variability in response to ICS and LTRAs, we did identify characteristics of patient that should guide the clinician in the choice of asthma medications.